资讯

Shares of Illumina Inc. (NASDAQ:ILMN) dropped 3.8% on Wednesday after Citi downgraded the stock from Neutral to Sell, warning ...
Investing.com -- Illumina (NASDAQ: ILMN) stock declined 3.8% Wednesday after Citi downgraded the genomic sequencing company to Sell from Neutral, citing concerns about its second-half outlook.
In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...
Novogene Europe announces the installation of its fifth Illumina NovaSeq X Plus sequencing system, expanding high-throughput ...
MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader ...
Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.
Illumina expects the addition of a high-margin revenue stream, although the deal is expected to close in 2026.
Less than two years after Boulder-based biotech firm SomaLogic Inc. merged with Standard BioTools Inc. (Nasdaq: LAB), Illumina Inc. (NASDAQ: ILMN) has inked a deal to absorb SomaLogic’s business ...